Milk allergy immunotherapy - DBV Technologies

Drug Profile

Milk allergy immunotherapy - DBV Technologies

Alternative Names: EPIT® Milk; Viaskin® Milk

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator DBV Technologies
  • Developer DBV Technologies; The Childrens Hospital of Philadelphia
  • Class Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Eosinophilic oesophagitis; Milk hypersensitivity

Most Recent Events

  • 08 Nov 2016 DBV Technologies completes enrolment in the phase II or Part B portion of the phase I/II MILES study for Milk hypersensitivity in USA and Canada
  • 21 Sep 2016 Milk allergy immunotherapy - DBV Technologies receives Fast Track designation for Milk hypersensitivity [Topical,Patch] (In adolescents, In children) in USA
  • 21 Mar 2016 Adverse events data from a phase I/II trial in Milk hypersensitivity presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top